Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

J-REGISTER: Japanese REal-world Data for Treatment of Afatinib (GIotrif®) in First-line Setting and Subsequent Therapies for Patients With Advanced EGFR Mutation-positive Lung Adenocarcinoma

NCT04795245 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04795245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04795245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
J-REGISTER: Japanese REal-world Data for Treatment of Afatinib (GIotrif®) in First-line Setting and Subsequent Therapies for Patients With Advanced EGFR Mutation-positive Lung Adenocarcinoma
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
August 26, 2021
Completion date
October 16, 2023
Enrollment
805 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous, non-small cell lung cancer